The agency’s ‘no-go’ for BioMarin’s hemophilia A gene therapy came as a surprise, but reflects outstanding questions as to the durability of the treatment.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. A reprieve from hemophilia A, but for how long?. Nat Biotechnol 38, 1107–1109 (2020). https://doi.org/10.1038/s41587-020-0693-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-0693-y
- Springer Nature America, Inc.